|
**Overview**: Trio WES (Trio Whole Exome Sequencing) Panel**Introduction**: The Trio WES Panel is a diagnostic tool designed to screen for genetic disorders using whole blood samples from proband and parents. In India, rare genetic disorders affect ~70-96 million people, with undiagnosed cases high in rural/low-SES families due to consanguinity and limited access to advanced sequencing. High morbidity from delayed diagnosis leading to prolonged diagnostic odyssey, inappropriate treatments, or recurrence in subsequent pregnancies. Per genetics practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs PCR/WES for proband and parental exomes over 1-2 days (analysis time longer) with high diagnostic yield (~30-50 percent in neurodevelopmental disorders), valuable for identifying de novo or inherited variants. This diagnostic falls under genetic screening and targets children with developmental delay, intellectual disability, dysmorphism, or unexplained syndromes, addressing accurate detection to guide management, counseling, or therapy. With elevated burden due to underdiagnosis, the test supports public health efforts by enabling precise molecular diagnosis and reducing recurrence risk. Its whole blood-based approach ensures reliable trio analysis.**Other Names**: Trio WES Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: Trio WES standard for rare diseases since 2010s; in India, expanding in genetic centers.**Purpose**: The test assesses 3 parameters including proband WES to guide genetic disorder screening, identify variants, inform counseling.**Test Parameters**: 1. Proband WES, 2. Parent 1 WES, 3. Parent 2 WES.**Pretest Condition**: No fasting required; patients should have unexplained phenotype.**Specimen**: 3 mL whole blood in 1 EDTA tube (trio samples), transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for sequencing).**Medical History**: Parents should provide details on child's symptoms, family history.**Consent**: Written informed consent (including genetic counseling) is required, detailing the test's purpose, potential risks of VUS/incidental findings, benefits of diagnosis, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using WES by trained personnel to ensure sterile technique, variant calling, and interpretation within weeks using provided databases/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Pathogenic variant identification confirms diagnosis, necessitating specialist input.**Specialist Consultation**: Medical geneticists should be consulted for management.**Additional Supporting Tests**: Sanger confirmation, segregation analysis.**Test Limitations**: Non-coding variants missed; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Genetic Studies India 2023. |
